One of the main problems related to the management of prostate cancer is the widely varying clinical behaviour from`autopsy cancer' that is never a threat to the host, to rapidly progressive disease unresponsive to any currently available therapy. The DoD Centre for Prostate Disease Research has built an infrastructure to attempt to study biomarkers to better characterise the disease in individual patients. Starting in 1994, a prospective, comprehensive multicentre database was developed and the programme currently maintains and updates information on over 4,100 men from Walter Reed AMC as well as approximately 8,000 patients from eight other military medical centres. In 1996, a tumour tissue repository was developed for fresh and archival materials linked to the database by dual patient consent. The centre has studied a number of individual molecular biomarkers including p53, bcl-2, KI-67(MIB-1), CD34 (angiogenesis), p16, p27, C-erbB-2, Maspin, RT-PCR-PSA of blood and bone marrow, and ras. Current work is involved with developing a cDNA microarray gene chip to study many genes simultaneously in clinical samples to better predict clinical stage and behaviour. A chip with androgen regulated genes as well as many more genes of interest has been developed.
Biologic effects of androgens on prostatic epithelial cells involve androgen receptor (AR) mediated cell signalling. Abrogation of the androgen signalling pathway would ultimately translate into altered transcriptional regulation of the genes regulated by the AR. Therefore, an expression pro®le of androgen responsive genes (ARGs) has the potential to serve as a read-out of the status of AR signalling. Such a read-out may also de®ne potential biomarkers for the onset and/or progression of prostate cancers. To obtain a comprehensive set of ARGs in the prostate, expression pro®le in LNCaP cells was evaluated by serial analysis of gene expression (SAGE), which provides both quantitative and high throughput analyses with respect to global gene expression pro®les of known as well as novel transcripts. Comparison of transcripts between control and R1881 treated LNCaP cells revealed the induction of 136 genes and repression of 215 genes in response to androgen (P`0.05). A high fraction ( 90%) of ARGs identi®ed by SAGE have not been described as ARGs previously. On the basis of the SAGE de®ned ARGs, other genes involved in androgen biosynthesis and AR functions, prostate speci®c sequences and human genes commonly involved in prostate and other cancers, we have developed a cDNA microarray for prostate-androgen signalling associated proteins (ASAP). The prostate-ASAP chip has utility in studying gene modulations by normal and/or abnormal androgen signalling in the prostate, as well as in identifying new putative diagnostic and/or therapeutic targets for prostate cancer. This chip will also be systematically used to analyse a large cohort of prospectively followed radical prostatectomy patients as well as samples from patients with advanced and HRPC disease.
